



(12) **Oversettelse av
europeisk patentskrift**

(11) **NO/EP 2916871 B1**

NORGE

(19) NO

(51) Int Cl.

A61K 47/20 (2006.01)

A61K 9/14 (2006.01)

A61K 9/16 (2006.01)

A61K 31/57 (2006.01)

A61P 15/00 (2006.01)

A61P 15/18 (2006.01)

Patentstyret

(21)	Oversettelse publisert	2017.01.23
(80)	Dato for Den Europeiske Patentmyndighets publisering av det meddelte patentet	2016.09.14
(86)	Europeisk søknadsnr	13801639.9
(86)	Europeisk innleveringsdag	2013.11.07
(87)	Den europeiske søknadens Publiseringsdato	2015.09.16
(30)	Prioritet	2012.11.08, FR, 1260603
(84)	Utpekte stater	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
(73)	Innehaver	Laboratoire HRA Pharma, 15, rue Béranger, 75003 Paris, FR-Frankrike
(72)	Oppfinner	BATTUNG, Florian, 4 rue Paulin Mery, F-75013 Paris, FR-Frankrike JUVIN, Pierre-Yves, 146 boulevard des anglais, F-44100 Nantes, FR-Frankrike HECQ, Jérôme, 5bis chemin de Sissan, F-33360 Camblanes et Meynac, FR-Frankrike COLIN, Aude, 21bis rue Bonnefin, F-33100 Bordeaux, FR-Frankrike
(74)	Fullmektig	Bryn Aarflot AS, Postboks 449 Sentrum, 0104 OSLO, Norge


(54)	Benevnelse	CO-MICRONISATION PRODUCT COMPRISING ULIPRISTAL ACETATE
(56)	Anførte publikasjoner	EP-A1- 2 471 537 WO-A1-00/28970 US-A1- 2009 192 130

Field of the invention

The present invention relates to a novel galenic form of ulipristal acetate, more specifically to a co-micronisation product, and to pharmaceutical compositions containing said galenic form.

Technical background of the invention

Ulipristal acetate (abbreviated as UPA) corresponds to 17 α -acetoxy-11 β -[4-(N,N-dimethylamino)-phenyl]-19-norpregna-4, 9-diene-3,20-dione (IUPAC nomenclature) and has the following chemical formula:



Its synthesis is described, *inter alia*, in patent EP 0 422 100 and in patent application EP 1 602 662.

Ulipristal acetate is a synthetic selective progesterone receptor modulator. By virtue of its action on the progesterone receptor, ulipristal acetate is capable of exerting a contraceptive action by inhibiting or delaying ovulation. Clinical studies showed that ulipristal acetate, administered in a single dose of 30 mg, makes it possible to prevent an unwanted pregnancy when it is administered within 120 hours following unprotected or poorly protected sexual intercourse (Glasier et al., Lancet. 2010, 375(9714):555-62; Fine et al., Obstet Gynecol. 2010, 115:257-63). Ulipristal acetate has thus been authorised as an emergency contraceptive and is marketed under the trade name EllaOne® in Europe.

Other therapeutic applications of ulipristal acetate were proposed in the prior art. Recent clinical trials showed that the chronic administration of ulipristal acetate (at 5 mg or 10 mg per day) makes it possible to significantly reduce the symptoms associated with uterine fibromas and provides a therapeutic benefit which is greater than that of the reference treatment, namely leuprolide acetate (Donnez et al., N Engl J Med. 2012; 366(5):421-32). On the basis of these clinical trials, the European Medicines Agency (EMA) authorised, in February 2012, the

proprietary drug Esmya® (5mg of ulipristal acetate) for the pre-operative treatment of symptoms associated with uterine fibromas.

The pharmaceutical compositions currently marketed comprise ulipristal acetate in a micronised form.

- 5 The proprietary drug Esmya® is provided in the form of an uncoated tablet comprising 5 mg of micronised ulipristal acetate combined with the following excipients: microcrystalline cellulose, mannitol, sodium croscarmellose, talc and magnesium stearate.

EllaOne® is, for its part, provided in the form of an uncoated tablet comprising 30 mg of micronised ulipristal acetate and the following excipients: lactose monohydrate, povidone K30,
10 sodium croscarmellose and magnesium stearate.

Additional pharmaceutical compositions have been described in international application WO 2010/066749.

The development of new galenic forms suitable for the administration of ulipristal acetate remains a major challenge for therapeutic and contraceptive uses of ulipristal acetate.

- 15 In this regard, there is, at the current time, a need for new pharmaceutical formulations containing ulipristal acetate and having suitable release properties and a suitable bioavailability.

Summary of the invention

A subject of the present invention is a co-micronisation product comprising (i) an active principle
20 selected from the group consisting of ulipristal acetate, a metabolite of ulipristal acetate, and mixtures thereof, and (ii) a pharmaceutically acceptable solid surfactant.

In certain embodiments, the co-micronisation product according to the invention has one or more of the following features:

- the weight ratio between the active principle and the surfactant is included in a range
25 from 0.1 to 10, preferably 0.5 to 4,
- the surfactant is selected from C₈-C₂₀ alkyl sulphate salts and mixtures thereof, preferably sodium dodecyl sulphate,
- the active principle is selected from the group consisting of ulipristal acetate, 17 α -acetoxy-11 β -(4-N-methylaminophenyl)-19-norpregna-4,9-diene-3, 20-dione, 17 α -
30 acetoxy-11 β -(4-aminophenyl)-19-norpregna-4, 9-diene-3,20-dione and mixtures thereof, and/or
- a d50 of less than 20 μ m, preferably of less than 15 μ m, and/or a d90 of less than 50 μ m, preferably of less than 40 μ m.

A subject of the present invention is also a method for preparing a co-micronisation product as previously defined, comprising the steps consisting in:

- a) providing an active principle selected from the group consisting of ulipristal acetate, a ulipristal acetate metabolite and mixtures thereof,
- 5 b) mixing the active principle of step a) with the surfactant and
- c) co-micronising the mixture obtained in step b).

The active principle of step a) may be in micronised or non-micronised form.

An additional subject of the invention is a pharmaceutical composition comprising a co-micronisation product as previously defined and a pharmaceutically acceptable excipient. The
10 pharmaceutically acceptable excipient is preferably selected from the group consisting of a diluent, a binder, a flow agent, a lubricant, a disintegrant and mixtures thereof.

In certain embodiments, the pharmaceutical composition comprises:

- 0.5% to 80% of co-micronisation product,
- 0% to 10% of disintegrant,
- 15 - 15% to 95% of diluent, and
- 0% to 5% of lubricant,

the percentages being expressed by weight relative to the total weight of the composition.

Preferably, the pharmaceutical composition according to the invention comprises from 1 mg to 100 mg, preferably from 1 mg to 40 mg, of active principle per dose unit. It is preferably intended
20 to be administered orally and may be in the form of a powder, a granule, a film-coated or uncoated tablet, or a capsule.

A subject of the present invention is also a co-micronisation product or a pharmaceutical composition, as previously defined, for use as a contraceptive, for example, as a regular
25 contraceptive or as an emergency contraceptive.

Finally, a subject of the invention is also a co-micronisation product or a pharmaceutical composition, as previously defined, for use in the treatment or prevention of a gynaecological disorder, preferably affecting the uterus.

30 **Figures**

Figure 1 shows the *in vitro* dissolution curves for various co-micronisates (see Example 1 hereinafter): UPA/SDS 7/3 (open square), UPA/kollicoat® IR 7/3 (solid square), UPA/citric acid monohydrate 7/3 (open triangle), UPA/fumaric acid 7/3 (open circle). Control experiment:

micronised UPA (alone – in the absence of excipient) (solid diamond). y-axis: percentage of UPA released (%), x-axis: time in minutes.

Figure 2 shows the *in vitro* dissolution curves for various co-micronisates (see Example 1 hereinafter): UPA/SDS 7/3 (open square), UPA/SDS 6/4 (solid circle), UPA/SDS 5/5 (solid square),
5 UPA/SDS/tartaric acid 6/3/1 (open triangle), Control experiment: micronized UPA (alone – in the absence of excipient – (solid diamond)). y-axis: percentage of UPA released (%), x-axis: time in minutes.

Figure 3 shows the *in vitro* dissolution curves for various batches of UPA/SDS 1/1 co-micronisates which differ in terms of their particle size distribution and/or the source of UPA
10 (see Example 3 hereinafter): Batch No. 1 (solid diamond), batch No. 2 (open square), batch No. 3 (solid circle), batch No. 4 (open triangle), Control experiment: micronised UPA (alone – in the absence of excipient – (solid square)). y-axis: percentage of UPA released (%), x-axis: time in minutes.

Figure 4 shows the *in vitro* dissolution curves for tablets comprising the UPA/SDS 1/1 co-micronisate (see Example 6 hereinafter): Tablet No. 1 (solid diamond), Tablet No. 2 (open
15 triangle), y-axis: percentage of UPA released (%), x-axis: time in minutes.

Detailed description of the invention

Co-micronisation product according to the invention and preparation method

20 At the end of lengthy research, the applicant showed that it is possible to significantly improve the *in vitro* dissolution and the *in vivo* bioavailability of ulipristal acetate (hereinafter UPA) by virtue of a co-micronisation technology.

Surprisingly, the applicant showed that the product resulting from the co-micronisation of ulipristal acetate with sodium dodecyl sulphate (also hereinafter called SDS or sodium lauryl
25 sulphate) has an *in vitro* dissolution rate which is significantly higher than that of UPA micronised alone, in the absence of excipient. This increase in the dissolution rate of UPA is also observed when the co-micronisation product is integrated into a pharmaceutical composition (see Example 6 hereinafter). The positive effect of the co-micronisation on the properties of UPA was confirmed *in vivo* by pharmacokinetic studies conducted in animals by the applicant. These
30 studies demonstrated that the UPA/SDS co-micronisation product has a bioavailability and a rate of absorption for UPA which are higher than those observed for UPA in micronised form (see Example 5 hereinafter).

By virtue of its improved pharmacokinetic properties, the co-micronisation product is expected to make it possible to reduce the doses of UPA to be administered in order to obtain the desired therapeutic or contraceptive effect. The decrease in the dose of UPA should make it possible, *inter alia*, to increase the safety, in particular the innocuousness, of the final pharmaceutical compositions. The applicant has shown that the dissolution rate and the pharmacokinetic properties of UPA in the co-micronisation product are particularly improved when a surfactant, in particular sodium dodecyl sulphate, is used as co-micronisation excipient. Notably, the co-micronisation does not systematically result in an improvement of the dissolution properties of UPA. The co-micronisation excipients tested by the applicant in Example 1 hereinafter, which are not surfactants, have proved to be ineffective in improving the *in vitro* dissolution properties of UPA. In particular, contrary to what the skilled artisan could have anticipated with regard to the dissolution properties of UPA in an acidic medium, the co-micronisation of UPA with an organic acid led to a clear decrease in the *in vitro* dissolution rate (see Example 1 hereinafter). Moreover, the applicant has demonstrated that the product obtained by intimate mixing of SDS and micronised UPA exhibits *in vitro* dissolution properties which are inferior to those of the product resulting from the co-micronisation of said mixture (see Example 2), even after incorporation into a pharmaceutical composition (see Example 6). All of these results emphasise that the improvement in the dissolution properties of UPA in the co-micronisates results from the specific combination (i) of the co-micronisation technology and (ii) of the use of a surfactant, in particular SDS, as co-micronisation excipient.

Thus, a subject of the present invention is a novel galenic form, more specifically a co-micronisation product comprising:

- an active principle selected from the group consisting of ulipristal acetate, a ulipristal acetate metabolite and mixtures thereof, and
- a pharmaceutically acceptable solid surfactant.

The term "co-micronisation product" (also hereinafter denoted co-micronisate) is intended to mean the product obtained by micronising a mixture comprising an active principle and at least one excipient. In the case in point, it is a solid mixture in the form of a powder.

In the context of the present invention, the term "micronisation" is intended to mean a method which makes it possible to reduce the size of the particles of a powder, for example by milling.


The reduction in the size of the particles is evidenced by a decrease of at least 10% of a parameter selected from the d50, the d10 and the d90. A reduction of "at least 10%" encompasses a reduction of at least 20%, of at least 30%, of at least 40% and of at least 50%.

The micronisation can be carried out by means of commercially available devices, such as ball or air-jet micronisers.


In the context of the present invention, the term "a micronised product" is intended to mean a product which is in the form of a powder having a d90 of less than 50 μm .

Thus, preferably, the co-micronisation product according to the invention has a d90 of less than 50 μm .


UPA metabolites are described, *inter alia*, in Attardi et al., Journal of Steroid Biochemistry and Molecular Biology, 2004, 88: 277-288 and illustrated hereinafter:




Monodemethylated UPA
derivative



Didemethylated
UPA derivative



17 α -Hydroxy UPA derivative



UPA derivative comprising an
aromatic ring

Preferably, the ulipristal acetate metabolite is selected from:

- 17 α -acetoxy-11 β -(4-N-methylaminophenyl)-19-norpregna-4,9-diene-3,20-dione (monodemethylated derivative) and
- 17 α -acetoxy-11 β -(4-aminophenyl)-19-norpregna-4,9-diene-3,20-dione (didemethylated derivative).

In one preferred embodiment of the co-micronisate according to the invention, the active principle is selected from the group consisting of 17 α -acetoxy-11 β -(4-N-methylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, 17 α -acetoxy-11 β -(4-aminophenyl)-19-norpregna-4,9-diene-3,20-dione, ulipristal acetate and mixtures thereof.

5

The pharmaceutically acceptable surfactant is preferably selected from the surfactants commonly used in galenics which can undergo co-micronisation, and mixtures thereof. The term "solid surfactant" is intended to mean a surfactant which is solid at ambient temperature, i.e. typically at approximately 20°C. In certain advantageous embodiments, the surfactant has a high melting point, preferably above 50°C and even more preferably above 100°C.

10

Preferably, the surfactant is selected from C₈-C₂₀, preferably C₁₀-C₁₄, alkyl sulphate salts, and mixtures thereof.

In one advantageous embodiment, the surfactant is selected from the dodecyl sulphate salts, preferably the alkali metal or alkaline-earth metal salts thereof, such as a sodium, magnesium or calcium salt.

15

As is exhaustively demonstrated by the examples of the present application, a surfactant that is particularly suitable for obtaining a co-micronisation product according to the invention is SDS, i.e. sodium dodecyl sulphate, also known as sodium lauryl sulphate (abbreviated as SLS). Thus, in a preferred embodiment, the surfactant is sodium dodecyl sulphate.

20

- In other embodiments, the co-micronisation product according to the invention comprises:
- an active principle selected from the group consisting of 17 α -acetoxy-11 β -(4-N-methylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, 17 α -acetoxy-11 β -(4-aminophenyl)-19-norpregna-4,9-diene-3,20-dione, ulipristal acetate and mixtures thereof, preferably ulipristal acetate, and
 - sodium dodecyl sulphate as co-micronisation excipient.

25

The weight ratio between the active principle and the surfactant is generally included in a range from 0.1 to 10, preferably from 0.5 to 4. An active principle/surfactant weight ratio of from 0.5 to 4 encompasses a weight ratio of from 0.5 to 1, from 1 to 1.5, from 1.5 to 2, from 2 to 2.5, from 3 to 3.5, and from 3.5 to 4.

30

Preferably, the active principle/surfactant weight ratio is included in a range from 0.8 to 2.5. A suitable active principle/surfactant weight ratio is, for example, a weight ratio ranging from 0.8 to 1.2, such as a weight ratio of 1.

As has been shown in the examples, the particle size distribution (i.e. the distribution of the size of the particles) of the co-micronisation product can have an effect on the UPA solubility properties. It is preferable for the d50 of the co-micronisation product to be less than 25 μm , preferably less than 20 μm , or even less than 15 μm .

- 5 A d50 of less than 15 μm encompasses a d50 of less than 12 μm , than 11 μm , than 10 μm , than 9 μm , than 8 μm , than 7 μm , than 6 μm , than 5 μm , and than 4 μm .

It is also preferable for the d90 of the co-micronisation product to be less than 50 μm , or even less than 40 μm . A d90 of less than 40 μm encompasses a d90 of less than 38 μm , than 37 μm , than 36 μm , than 35 μm , than 34 μm , than 33 μm , than 32 μm , than 31 μm , than 30 μm , than
 10 29 μm , than 28 μm , than 27 μm , than 26 μm , than 25 μm , than 24 μm , than 23 μm , then 22 μm , than 21 μm , than 20 μm , than 19 μm , than 18 μm , than 17 μm , than 16 μm , than 15 μm , than 14 μm , than 13 μm , than 12 μm , than 11 μm , and than 10 μm .

In certain embodiments, the co-micronisation product according to the invention is characterised in that its particle size distribution has:

- 15 - a d50 of less than 20 μm , preferably less than 15 μm , and/or
 - a d90 of less than 50 μm , preferably less than 40 μm and even more preferably less than 30 μm .

By way of example, the co-micronisate according to the invention may have a d50 of less than 5 μm and/or a d90 of less than 15 μm .

- 20 The d10 of the co-micronisate according to the invention is generally greater than 0.05 μm .

In the context of the present invention, "a d50 of less than X μm " means that at least 50% of the co-micronisate particles have a size of less than X μm .

"A d90 of less than Y μm " means that at least 90% of the co-micronisate particles have a size of less than Y μm .

- 25 Likewise, "a d10 of greater than Z μm " means that at least 90% of the co-micronisate particles have a particle size greater than Z μm .

The granulometry – i.e. the distribution of the size of the particles – of the co-micronisation product, and in particular the d90, d50 and d10 parameters, can be determined by any method known to those skilled in the art. Preferably, laser diffraction will be used. Example 3 hereinafter
 30 proposes conditions for implementing this method.

In certain embodiments, the co-micronisate may comprise one or more excipients in addition to the surfactant. The additional excipient(s) may be selected from a diluent, a binder, a

disintegrant and mixtures thereof. In certain embodiments, the additional excipient(s) is (are) polymeric. By way of example, they may be selected from N-vinyl-2-pyrrolidone polymers and copolymers, such as a copovidone, a povidone or a crospovidone.

- 5 In certain particular embodiments, the co-micronisate according to the invention comprises:
- an active principle selected from the group consisting of ulipristal acetate, a ulipristal acetate metabolite and mixtures thereof,
 - a pharmaceutically acceptable solid surfactant, preferably SDS, and
 - an additional excipient selected from the group consisting of N-vinyl-2-pyrrolidone
- 10 polymers and copolymers and mixtures thereof, preferably a crospovidone, a povidone and mixtures thereof.

The additional excipient may be present in an amount corresponding to an "active principle/additional excipient" weight ratio of from 0.1 to 10, preferably from 0.5 to 4.

- 15 In one additional embodiment, the co-micronisate is devoid of additional excipient, i.e. devoid of an excipient other than the surfactant. In particular, the co-micronisate according to the invention may consist of the active principle and the surfactant.

As is illustrated in the examples, the co-micronisation product has improved properties in terms of bioavailability and *in vitro* dissolution of the active principle. In certain embodiments, the co-micronisation product according to the invention is characterised in that at least 80% of the active principle that it contains is released within 30 minutes when said co-micronisation product is subjected to an *in vitro* dissolution test, preferably as defined in the European Pharmacopoeia §2.9.3.

- 25 The *in vitro* dissolution test can be carried out using any commercially available device comprising paddles. Example 1 hereinafter presents implementing conditions for determining the *in vitro* dissolution rate of a co-micronisate according to the invention. Briefly, an amount of co-micronisate representing 30 mg of active principle is placed in a gelatin gel capsule. This gel capsule is then placed in 900 ml of a medium buffered at gastric pH, comprising 0.1% of SDS, at
- 30 $37 \pm 0.5^\circ\text{C}$, and subjected to stirring at 50 revolutions per minute (rpm) (speed of rotation of the paddles of the dissolution device). The dissolution of the active principle in the medium can be monitored by spectrophotometry at the maximum wavelength of absorbance. A gastric pH is typically a pH of 1 to 3.

A subject of the present invention is also a method for preparing the co-micronisate described above comprising the steps consisting in:

- a) providing an active principle selected from the group consisting of ulipristal acetate, a ulipristal acetate metabolite and mixtures thereof,
- 5 b) mixing the active principle of step a) with a pharmaceutically acceptable surfactant and
- c) micronising the mixture obtained in step b).

As shown in the examples, the active principle provided in step a) may be in micronised or non-
10 micronised form. Moreover, the active principle may be amorphous or crystalline. Preferably, the active principle provided in step a) is in a crystalline form.

The surfactant used in step b) may be non-micronised or micronised.

The micronisation step c) may be carried out using a commercially available micronisation system. It may in particular be an air-jet microniser or a ball microniser. Those skilled in the art,
15 by virtue of their general knowledge and the performing of routine experiments, will be able to determine the conditions for carrying out step c) in order to obtain a co-micronisation product having the desired particle size distribution. By way of example, when step c) is carried out using an air-jet microniser, the skilled artisan will be able to vary the powder feed flow and the pressure of the air jets in order to modulate the particle size distribution of the final co-
20 micronisate.

Pharmaceutical composition according to the invention

The co-micronisation product is intended mainly for therapeutic or contraceptive use. For this purpose, it can be administered directly or inserted into an administration device such as a
25 vaginal ring, a patch, an intrauterine device or an implant.

Generally, the co-micronisation product according to the invention is integrated into a pharmaceutical composition so as to facilitate its administration. Thus, an additional subject of the present invention is a pharmaceutical composition comprising a co-micronisation product as previously defined and at least one pharmaceutically acceptable excipient.

30 The skilled artisan will be able to choose the excipient(s) to be combined with the co-micronisation product according to the final form of the pharmaceutical composition, the desired route of administration and the desired active principle release profile. For this purpose, the skilled artisan will be able to refer to the following reference works: Remington: The Science

and Practice of Pharmacy (Lippincott Williams & Wilkins; Twenty first Edition, 2005) and, Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (Pharmaceutical Press; 6th revised edition, 2009).

- 5 The pharmaceutical composition and the co-micronisate according to the invention may be administered by any route, in particular the oral, buccal, nasal, sublingual, vaginal, intra-uterine, rectal or transdermal route or by the parenteral route, for example by intravenous injection. The preferred routes of administration are the buccal, oral, intra-uterine and vaginal routes.
- 10 The pharmaceutical composition according to the invention may be in any form, for example in the form of a tablet, a powder, a capsule, a pill, a suppository, a vaginal suppository, a suspension, an aqueous, alcoholic or oily solution, a syrup, a gel, an ointment, an emulsion, a lyophilisate or an orodispersible film. The route of administration and the galenic form of the pharmaceutical composition may depend on the desired therapeutic or contraceptive effect.

15

- In certain embodiments, the pharmaceutical composition according to the invention may be integrated into a device enabling prolonged administration of the active principle. The pharmaceutical composition may in particular be incorporated into a vaginal ring, into an intrauterine device, into a patch, for example a transdermal or mucoadhesive patch, or into an
- 20 implant, for example an implant of contraceptive type. For examples of vaginal rings suitable for implementing the invention, reference may be made to application WO 2006/10097.

- In additional embodiments, the pharmaceutical composition according to the invention is in solid form. Preferably, the pharmaceutical composition according to the invention is solid and is
- 25 intended for oral administration.

- In certain embodiments, the pharmaceutical composition according to the invention is characterised in that the pharmaceutically acceptable excipient is selected from the group consisting of a diluent, a binder, a flow agent, a lubricant, a disintegrant and mixtures thereof.

30

For the purposes of the present invention, a diluent may be one or more compounds capable of densifying the active principle so as to obtain the desired mass. The diluents encompass inorganic phosphates, monosaccharides and polyols such as xylitol, sorbitol, lactose, galactose,

xylose or mannitol, disaccharides such as sucrose, oligosaccharides, polysaccharides such as cellulose and its derivatives, starches, and mixtures thereof. The diluent may be in anhydrous or hydrated form.

By way of example, a suitable diluent may be selected from microcrystalline cellulose, mannitol,
5 lactose and mixtures thereof.

The binder may be one or more compounds capable of improving the aggregation of the active principle with the diluent. By way of example of binders, mention may be made of hydroxypropyl cellulose, hydroxypropylmethyl cellulose, povidone (polyvinylpyrrolidone), copolymers of N-
10 vinyl-2-pyrrolidone and of vinyl acetate (copovidone), and mixtures thereof.

The lubricant may be one or more compounds capable of preventing the problems associated with the preparation of dry galenic forms, such as the sticking and/or gripping problems which occur in machines during compression or filling. The preferred lubricants are fatty acids or fatty
15 acid derivatives, such as calcium stearate, glyceryl monostearate, glyceryl palmitostearate, magnesium stearate, zinc stearate, or stearic acid, polyalkylene glycols, in particular polyethylene glycol, sodium benzoate or talc. The lubricants that are preferred according to the invention are the stearate salts and mixtures thereof. A suitable lubricant is, for example, magnesium stearate.

20

The flow agent optionally used according to the invention may be selected from compounds which contain silicon, for example talc, anhydrous colloidal silica or precipitated silica.

The disintegrant can be used to improve the release of the active principle. It may be selected,
25 for example, from crosslinked polyvinylpyrrolidone (crospovidone), crosslinked carboxymethylcellulose (such as sodium croscarmellose) or non-crosslinked carboxymethylcellulose, starches and mixtures thereof. The disintegrant is preferably selected from the group consisting of a sodium croscarmellose, a crospovidone and mixtures thereof.

30 In certain embodiments, the composition according to the invention comprises:

- 0.5% to 80% of the co-micronisation product as previously defined,
- 0% to 10% of disintegrant,
- 15% to 95% of diluent, and

- 0% to 5% of lubricant,

the percentages being expressed by weight relative to the total weight of the composition.

The composition according to the invention may in addition be characterised in that it

- 5 comprises from 0% to 20% by weight of a binder, and from 0% to 5% by weight of a flow agent.

In other embodiments, the composition according to the invention comprises:

- 1% to 65% of the co-micronisation product as previously defined,
- 0% to 10% of disintegrant, preferably selected from a sodium croscarmellose, a
- 10 crosppovidone and mixtures thereof,
- 25% to 95% of diluent, preferably selected from mannitol, lactose, microcrystalline cellulose and mixtures thereof, and
- 0% to 5% of lubricant, preferably a stearate, such as magnesium stearate,

the percentages being expressed by weight relative to the total weight of the composition.

15

In one additional embodiment, the composition according to the invention comprises:

- 1% to 45% of the co-micronisation product,
- 0% to 10% of disintegrant, preferably selected from a sodium croscarmellose, a
- 20 crosppovidone and mixtures thereof,
- 40% to 95% of diluent, preferably selected from mannitol, lactose, microcrystalline cellulose and mixtures thereof, and
- 0% to 3% of lubricant, preferably a stearate, such as magnesium stearate.

By way of example, the pharmaceutical composition according to the invention may comprise

25 from:

- 1% to 10% by weight of the co-micronisation product,
- 80% to 95% by weight of diluent,
- 1% to 8% by weight of disintegrant, and
- 0.1% to 2% of a lubricant,

30 the percentages being expressed by weight relative to the total weight of the composition.

A further example is a pharmaceutical composition comprising from:

- 35% to 45% by weight of co-micronisation product,

- 50% to 60% by weight of diluent,
- 1% to 8% by weight of disintegrant, and
- 0.1% to 2% of a lubricant,

the percentages being expressed by weight relative to the total weight of the composition.

5 It goes without saying that, in the examples described above, the co-micronisation product preferably comprises ulipristal acetate as active principle and sodium dodecyl sulphate as surfactant according to a weight ratio of 0.8 to 2.5.

The pharmaceutical composition according to the invention may also comprise one or more excipients in addition to the above mentioned excipients. The additional excipient(s) may be
10 selected from the group consisting of coating agents, such as coating agents based on polyvinyl alcohol or on hydroxypropylmethyl cellulose, pigments such as aluminium oxide or iron oxide, flavourings, wetting agents, waxes, dispersants, stabilisers and preservatives.

In certain embodiments, the pharmaceutical composition according to the invention is free of
15 binder and/or of flow agent. In other embodiments, the SDS present in the co-micronisation product is the only surfactant present in the pharmaceutical composition.

The pharmaceutical composition according to the invention may be prepared according to any one of the methods commonly used in galenics. These methods typically comprise mixing the
20 co-micronisation product according to the invention with one or more excipients, then shaping the mixture obtained. By way of example, when it is in the form of a tablet, the pharmaceutical composition according to the invention can be prepared by direct compression or by compression after dry or wet granulation.

25 In the embodiments described above of the pharmaceutical composition according to the invention, the co-micronisation product is preferably characterised in that it comprises UPA and SDS, the UPA/SDS weight ratio being from 0.5 to 4, preferably from 0.8 to 2.5. It goes without saying that the co-micronisation product integrated into the pharmaceutical composition according to the invention may have any one of the features described in the present
30 description. In particular, the co-micronisation product has one or more (1, 2, 3, 4 or 5) of the following features:

- i. the active principle is UPA and the surfactant is SDS,
- ii. the active principle/surfactant weight ratio is from 0.8 to 1.2,

- iii. the d50 of the co-micronisation product is less than 20 μm , preferably less than 15 μm ,
 - iv. the d90 of the co-micronisation product is less than 50 μm , preferably less than 40 μm ,
and
 - v. at least 80% of the active principle that the co-micronisation product contains is
5 released within 30 minutes when said co-micronisation product is subjected to an *in vitro* dissolution test, preferably under the following conditions:
 - device: paddle dissolution device,
 - sample: gelatin gel capsule containing an amount of co-micronisate
corresponding to 30 mg of active principle,
 - 10 - dissolution medium: 900 ml of an aqueous solution buffered at gastric pH
comprising 0.1% of SDS,
 - temperature: $37 \pm 0.5^\circ\text{C}$, and
 - paddle rotation speed: 50 revolutions per minute (rpm).
- 15 Another further example according to the invention is a pharmaceutical composition comprising
from:
- 4% to 10% by weight of co-micronisation product according to the invention, preferably
comprising UPA and SDS in a UPA/SDS weight ratio of from 0.8 to 2.5, preferably from
0.8 to 1.2,
 - 20 - 50% to 65% by weight of microcrystalline cellulose and from 25% to 35% by weight of
mannitol as diluents,
 - 1% to 8% by weight of crospovidone and/or of sodium croscarmellose as disintegrant,
and
 - 0.1% to 2% of magnesium stearate as lubricant.
- 25 As previously mentioned, the composition according to the invention may be in the form of a
powder, a granule, a film-coated or non-film-coated tablet, or a gel capsule, and is preferably
intended for oral administration. In certain embodiments, the pharmaceutical composition
according to the invention is in the form of a non-film-coated tablet intended for oral
administration.
- 30 The composition according to the invention may be a controlled-, immediate-, sustained- or
delayed-release pharmaceutical composition. Preferably, the composition according to the
invention is an immediate-release composition.

The term "immediate-release composition" is intended to mean a pharmaceutical composition characterised in that at least 75% of the active principle initially contained in a dose unit of the pharmaceutical composition is released within 45 minutes when said dose unit is subjected to an *in vitro* dissolution test, for example as defined in the European Pharmacopoeia §2.9.3, and preferably under the following conditions:

- paddle dissolution device,
- dissolution medium: aqueous solution buffered at gastric pH containing 0.1% of SDS,
- temperature: $37 \pm 0.5^\circ\text{C}$, and
- rotation speed: 50 rpm.

The volume of the dissolution medium depends on the amount of active principle contained in the dose unit. For a dose unit comprising 5 mg of active principle, 500 ml of dissolution medium are used. For a dose unit comprising 30 mg of active principle, 900 ml of dissolution medium are used.

In certain embodiments, the composition according to the invention is characterised in that at least 60%, or even at least 70%, of the active principle present in a dose unit is released within 20 minutes, when said dose unit is subjected to an *in vitro* dissolution test preferably carried out under the conditions described above.

The expression "at least 70% of the active principle present in a dose unit" encompasses at least 72%, at least 74%, at least 76%, at least 78%, at least 80%, at least 82%, and at least 86% of the active principle present in a dose unit.

In certain embodiments, the composition according to the invention is characterised in that at least 80% of the active principle present in a dose unit is released within 20 minutes, when said dose unit is subjected to an *in vitro* dissolution test preferably carried out under the conditions described above.

Generally, the pharmaceutical composition comprises from 1 mg to 100 mg of active principle per dose unit, preferably from 1 mg to 40 mg, or even from 2 mg to 30 mg, of active principle per dose unit. The dose of active principle depends on the therapeutic or contraceptive effect and on the administration scheme that are desired. For example, for certain applications, the amount of UPA per dose unit may be included in a range from 1 mg to 5 mg.

In emergency contraception, the active principle may be present in an amount of from 20 mg to 40 mg per dose unit.

In regular contraception, the active principle may be present in an amount of from 2 mg to 5 mg per dose unit.

For therapeutic uses such as the treatment of uterine fibromas, the active principle may be present in an amount of from 3 mg to 15 mg per dose unit.

The dose of active principle and the administration scheme may also depend on the personal parameters of the patient, in particular their weight, age, sex, general health condition and diet,
5 on the pathological conditions from which the patient is suffering, etc.

Finally, the pharmaceutical composition according to the invention may comprise an additional active principle. This additional active agent may exert an action different from that of UPA or its metabolites. It may also reinforce the therapeutic effect of UPA or its metabolites.

10

Therapeutic or contraceptive uses of the co-micronisate and of the pharmaceutical composition according to the present invention

In an additional aspect, a subject of the present invention is also a co-micronisation product or a pharmaceutical composition as previously described, for use as a medicament. The co-
15 micronisation product or the composition according to the invention is particularly suitable for use as a regular contraceptive or an emergency contraceptive. They can also be used for the treatment or prevention of hormonal, gynaecological or endocrine disorders, such as Cushing's disease. The composition or the co-micronisation product according to the invention can be used, in particular, in the treatment or prevention of a gynaecological disorder, preferably
20 affecting the uterus, including benign gynaecological disorders. The gynaecological disorders encompass, without being limited thereto, uterine fibromas and symptoms thereof, adenomyosis, endometriosis, pain associated with endometrium dislocation, and excessive uterine bleeding.

An additional subject of the invention is the use of the co-micronisation product according to
25 the invention for preparing a contraceptive or for preparing a medicament intended for the treatment or prevention of any one of the abovementioned pathological conditions.

A subject of the invention is also a method of contraception comprising the administration, to a patient, of a contraceptive dose of the co-micronisation product or of the pharmaceutical composition according to the invention.

30 The term "method of contraception" is intended to mean a method which makes it possible to prevent the occurrence of a pregnancy in a patient of child-bearing age.

In the case in point, it may be a method of emergency contraception. In this case, a single dose is preferably administered to the patient within an appropriate time period after unprotected

or poorly protected sexual intercourse, generally within 120 h following unprotected or poorly protected sexual intercourse.

The method of contraception may also be a method of regular contraception, in which the composition or the co-micronisation product are administered chronically and cyclically to the patient or continuously using a device such as an implant or a vaginal ring.

By way of alternative, the method of contraception may be a method of "on demand" contraception as described in international application WO 2010/119029.

Finally, a subject of the invention is also a method for treating a disease or a disorder in a patient, comprising the administration of a therapeutically effective dose of the co-micronisation product or of the pharmaceutical composition according to the invention to a patient, preferably a female patient. The therapeutic method according to the invention preferably relates to any one of the abovementioned diseases or disorders.

It goes without saying that, for the implementation of the methods and uses described above, the co-micronisation product and the pharmaceutical composition according to the invention may comprise one or more of the features explained in detail in the present description.

The objective of the examples hereinafter is to illustrate the invention more fully without, however, limiting the scope thereof.

EXAMPLES

Example 1: Screening of excipients for the co-micronisation of ulipristal acetate (UPA)

1. Materials and methods

Preparation of co-micronisates

The ulipristal acetate co-micronisation products (hereinafter "co-micronisates") were prepared according to the following method: The ulipristal acetate and the co-micronisation excipient to be tested were mixed in the desired weight ratio in a mortar and triturated until a homogeneous mixture was obtained. The mixture obtained was then micronised in a ball mill-homogeniser.

In vitro dissolution of the UPA co-micronisates

For each co-micronisate obtained, hard gelatin gel capsules containing an amount of co-micronisate corresponding to 30 mg of UPA per capsule were prepared. The studies of *in vitro*

dissolution of UPA as co-micronisate were carried out using these capsules according to the European Pharmacopoeia in §2.9.3, using a paddle dissolution device.

For each co-micronisate, a gel capsule containing said co-micronisate was placed in a bowl of the dissolution device containing 900 ml of a dissolution medium. The dissolution medium is an aqueous solution buffered at gastric pH and comprising 0.1% by weight of SDS. The conditions for carrying out the *in vitro* dissolutions are the following:

☐ Paddle rotation speed: 50 revolutions per minute (rpm)

☐ Temperature: 37°C ± 0.5°C

The dissolution of the UPA was monitored by spectrophotometry.

By way of control experiment, a gelatin gel capsule containing 30 mg of ulipristal acetate micronised alone (i.e. UPA micronised in the absence of any co-micronisation excipient) was used.

For each co-micronisate, the dissolution experiment was reproduced 3 times.

2. Results

☐ Screening of co-micronisation excipients

Table 1 below and Figure 1 show the dissolution results obtained for each co-micronisate prepared. The dissolution percentages are expressed relative to the initial amount of UPA contained in each gel capsule.

Table 1: Results of the *in vitro* dissolution assays for the UPA/excipient co-micronisates prepared. UPA/excipient weight ratio 7/3. Control experiment: UPA micronised alone.

Percentages of UPA released, expressed relative to the initial amount of UPA contained per gel capsule (Mean values over 3 experiments)					
Time (min)	UPA micronised alone	UPA/SDS	UPA/Kollicoat® IR	UPA/citric acid monohydrate	UPA/fumaric acid
0	0.0	0.0	0.0	0.0	0.0
1	0.0	0.0	0.2	0.1	1.1
5	5.5	5.3	0.5	0.5	1.2
7.5	15.00	15.8	0.7	0.6	1.8
10	22.30	31.9	0.9	0.8	2.1
15	30.00	67.3	1.1	1.1	2.3
20	34.30	80.5	1.4	1.6	2.9
30	39.50	85.8	2.5	2.6	5.7
45	47.50	89.3	5.3	4.7	11.0

Percentages of UPA released, expressed relative to the initial amount of UPA contained per gel capsule (Mean values over 3 experiments)					
Time (min)	UPA micronised alone	UPA/SDS	UPA/Kollicoat® IR	UPA/citric acid monohydrate	UPA/fumaric acid
60	53.80	91.5	8.8	7.1	16.4

It is specified that Kollicoat IR® is a polyethylene glycol/polyvinyl alcohol grafted copolymer.

These results show that the co-micronisation of ulipristal acetate with sodium dodecyl sulphate (SDS) makes it possible to very significantly improve the dissolution rate and the final amount of UPA released. Notably, the percentage of ulipristal acetate released into the dissolution medium at t = 20 min is approximately 80% for a gel capsule comprising the UPA/SDS co-micronisate, whereas it is only approximately 35% for a gel capsule containing ulipristal acetate which has been micronised in the absence of excipient.

The co-micronisate of UPA with Kollicoat IR® has a UPA release rate which is much lower than that observed for the micronised UPA since, after 60 min, less than 10% of the UPA initially contained in the co-micronisates has been released.

As is illustrated in Table 2 below, the solubility of the ulipristal acetate decreases very significantly according to the pH of the medium. It was therefore expected that the co-micronisation of ulipristal acetate with an acidic excipient – such as citric acid or fumaric acid – would make it possible to improve the dissolution of ulipristal acetate by decreasing the pH in the close surroundings of the dosage form and therefore by locally increasing its solubility.

Table 2: UPA solubility as a function of pH

pH	UPA solubility (g/l)
1.2	22.7
4.5	0.039
6.8	0.005

Surprisingly, contrary to what might have been expected with regard to the solubility of UPA in an acidic medium, the co-micronisation of UPA with an organic acid leads to a clear decrease in the UPA dissolution rate.

Conclusion

The co-micronisation in the presence of SDS made it possible to significantly increase the UPA dissolution rate and release rate *in vitro* compared with UPA in micronised form. On the other

hand, contrary to what might have been expected, the other co-micronisation excipients tested in Example 1 had a clearly negative impact on UPA release. The increase in the dissolution rate is therefore a specific effect of the SDS.

5 Influence of the UPA/SDS weight ratio on the *in vitro* dissolution of UPA

Various UPA/SDS co-micronisates were prepared according to the co-micronisation method described above in order to study the influence of the UPA/SDS weight ratio on the *in vitro* dissolution rate of UPA. By way of comparison, a UPA/SDS/tartaric acid co-micronisate in a 6/3/1 weight ratio was prepared in order to confirm the effect of a co-micronisation excipient of organic acid type on the dissolution of UPA.

The *in vitro* dissolutions obtained are illustrated in Figure 2 and presented in Table 3 hereinafter.

Table 3: *In vitro* dissolution of UPA as a function of the UPA/SDS weight ratio of the co-micronisates. Control experiments: UPA micronised alone and UPA/SDS/tartaric acid co-micronisate in a 6/3/1 molar ratio

	Percentages of UPA released, expressed relative to the initial amount of UPA contained per gel capsule (Mean values over 3 experiments)				
Time (min)	Micronised UPA (in the absence of excipient)	UPA/SDS 7/3	UPA/SDS 6/4	UPA/SDS 5/5	UPA/SDS /tartaric acid 6/3/1
0.0	0.0	0.0	0.0	0.0	0.0
1.0	0.0	0.0	0.2		0.0
5.0	5.5	5.3	33.4	14.2	3.4
7.5	15.00	15.8	52.2	21.1	5.0
10.0	22.30	31.9	67.4	44.0	8.3
15.0	30.00	67.3	75.2	73.2	16.8
20.0	34.30	80.5	78.8	90.7	21.7
30.0	39.50	85.8	82.3	99.0	30.6
45.0	47.50	89.3	92.3	102.9	47.4
60.0	53.80	91.5	94.5	104.4	53.9

Conclusion

The UPA dissolution rate increases with the decrease in the UPA/SDS weight ratio. The presence of a small proportion of tartaric acid in the co-micronisate has a negative impact on the UPA

dissolution rate which is not completely compensated by the presence of the SDS. This confirms the results obtained previously with fumaric acid and citric acid.

□ Other examples of co-micronisate

- 5 A UPA/SDS/crospovidone co-micronisate was prepared by co-micronisation of an intimate mixture of SDS, UPA and crospovidone in the weight ratios 5/2/3 using a ball mill-homogeniser. The *in vitro* dissolution profile is determined as described in point 1. above.

10 Table 4: UPA/crospovidone/SDS (5/2/3) co-micronisate. Percentages of UPA released, expressed relative to the initial amount of UPA contained per gel capsule (Mean values over 3 experiments)

Time (min)	% UPA released
0	0.0
1	0.4
5	7.1
7.5	18.0
10	28.0
15	58.3
20	67.6
30	80.7
45	85.4
60	86.8

Example 2: Comparison of the dissolution profile of a UPA/SDS co-micronisate compared with a UPA/SDS mixture

15

1. Materials and methods

The ulipristal acetate and the SDS were mixed in a 1/1 weight ratio in a mortar and triturated until a homogeneous mixture was obtained. A part of the mixture obtained was introduced into hard gelatin gel capsules in a proportion of 60 mg per gel capsule (i.e. 30 mg of UPA per gel capsule).

20

The remaining mixture was co-micronised using an air-jet microniser (Alpine AS 200 jet mill). Hard gelatin gel capsules were filled with 60 mg of the final co-micronisate (i.e. an amount of UPA of 30 mg/ capsule).

The dissolution of the UPA for the two types of capsules was studied under conditions and in a dissolution medium identical to those of Example 1.

2. Results

- 5 The dissolutions obtained for the UPA/SDS co-micronisate and the non-micronised UPA/SDS mixture (physical mixture) are illustrated in Table 5 below.

Table 5: *In vitro* dissolution of UPA in the dissolution medium of Example 1 using a co-micronisate UPA/SDS 1/1 and a physical mixture (not co-micronised) UPA/SDS 1/1.

Percentages of UPA released, expressed relative to the initial amount of UPA contained in each gel capsule (Mean values over 3 experiments)		
Time (min)	Co-micronisate UPA/SDS 1/1	Physical mixture UPA/SDS 1/1
0	0	0
3	29.6	32.2
5	69.3	61
7.5	86.2	68.4
10	94.3	71.8
15	96.4	76.2
20	96.8	79.3
30	97.4	83.4
45	97.9	86.9
60	98.1	88.8

- 10 The dissolution rate of the UPA is significantly higher for the co-micronisate than for the physical mixture after 20 minutes. This result shows that the co-micronisation has a direct impact on the *in vitro* dissolution of the UPA.

Example 3: Effect of the source of UPA and of the granulometry of the co-micronisate on the UPA dissolution rate

15

1. Materials and methods

Preparation of co-micronisates

The co-micronisates of ulipristal acetate with SDS were prepared using an air-jet microniser.

- 20 Briefly, the ulipristal acetate and the SDS were mixed in a 1/1 weight ratio in a mortar and triturated until a homogeneous mixture was obtained.

The mixture obtained was micronised in a microniser (Fluid Energy Loop Mill) according to the following conditions:

- ☐ Feed flow rate: 3 gr/min
- ☐ Venturi Pressure: 40 PSI
- 5 ☐ Mill Pressure from 10 to 120 PSI according to the desired particle size distribution.

The mill pressure was modulated so as to modify the granulometry of the final co-micronisate. The granulometry – i.e. the distribution of the size of the particles – of the resulting co-micronisates was determined by laser diffraction (Equipment: Malvern – Mastersizer 2000SM Scirocco 2000, optical model: Fraunhofer). The co-micronisates were prepared either from
 10 micronised ulipristal acetate, or from non-micronised ulipristal acetate. Table 6 hereinafter presents the granulometry of the batches of co-micronisates obtained as a function of the UPA source and the mill pressure.

Table 6: Particle size distribution of the various co-comicronisates UPA/SDS 1/1

Batch No.	UPA source	D10 (µm)	D50 (µm)	D90 (µm)
1	Non-micronised	2.54	21.35	143.89
2		0.79	3.32	10.03
3		0.69	2.48	6.00
4	micronised	0.51	1.36	3.76

15

☐ In vitro dissolution

For each batch of co-micronisate, hard gelatin capsules comprising 60 mg of co-micronisate (i.e. 30 mg of UPA per gel capsule) were prepared. The dissolution profiles were obtained under the conditions described in Example 1.

20

2. Results

☐ Effect of the UPA source

Figure 3 shows the dissolution curve for the UPA/SDS co-micronisate obtained from non-micronised UPA (batch No. 3, Figure 3: solid circle) and that of the UPA co-micronisate obtained
 25 from a micronised UPA source (batch No. 4, Figure 3: open triangle). It should be noted that the two co-micronisates have a similar granulometry (see batches No. 3 and No. 4 – Table 6). The two dissolution profiles show that the nature of the starting UPA – micronised or non-micronised – has no effect on the dissolution properties of the final co-micronisate.

□ Effect of the granulometry of the co-micronisate on UPA release

Table 7 below and Figure 3 illustrate the *in vitro* dissolution results obtained for the various batches of co-micronisate.

5 Table 7: *In vitro* dissolution results obtained for the batches of co-micronisates

	Percentages of UPA released, expressed relative to the initial amount of UPA contained per gel capsule (Mean values over 3 experiments)		
Time (min)	Batch No. 3	Batch No. 2	Batch No. 1
0	0	0	0
3	18	12.2	6.7
5	54.1	47.4	23.0
7.5	89.7	85.0	44.0
10	93.9	92.9	53.9
15	95	96.1	64.7
20	95.3	96.8	71.8
30	95.7	97.4	75.3
45	95.9	98.0	78.0
60	96	98.5	79.5

It appears that the dissolution rate and the final degree of dissolution of the UPA for batches No. 3 (Figure 3, solid circle) and No. 2 (Figure 3, open square) are higher than for batch No. 1 (Figure 3, solid diamond). This shows that the granulometry of the co-micronisate can have an effect on the UPA dissolution rate.

For information, it will be noted that co-micronisate No. 1, despite its coarse granulometry, has a UPA dissolution rate which is much higher than that observed for the UPA micronised alone (i.e. in the absence of co-micronisation excipient). This confirms, once again, the specific effect of the co-micronisation in the presence of SDS on the *in vitro* dissolution properties of UPA.

15

Example 5: Pharmacokinetic studies in rats

The objective of this study is to illustrate that the co-micronisation of ulipristal acetate with SDS makes it possible to improve the pharmacokinetic profile, in particular the bioavailability, of the UPA in comparison with micronised UPA.

20

1. Materials and methods

□ Animals

The pharmacokinetic study was carried out on female OFA(SD) rats weighing between 0.206 and 0.251 kg. The animals were deprived of food for 16 hours before the administration of the samples. The animals were placed in cages, the temperature of which was maintained between 20 and 25°C; the day/night cycles were 12 h each (6am - 6pm) and the air was conditioned using a ventilation system.

UPA samples

The samples tested are the following:

- Co-micronisate of ulipristal acetate/SDS, 1/1 ratio
- Powder of ulipristal acetate micronised in the absence of any excipient (UPA micronised alone)

Administration protocol

A predetermined amount of powder was administered by means of an oesophageal tube using a cannula. The powder was introduced into the stomach of each animal using a catheter. The dose administered corresponds to 4 mg of ulipristal acetate per kg.

Taking samples

Blood samples of 300 µl were taken from the (left or right) jugular of the rats. In order to avoid excessively high blood sampling, the rats were divided into 3 groups of 6 rats as follows:

Table 8: Sampling schedule

Sampling time	Rat groups		
	No. 1	No. 2	No. 3
Pre-administration (Time = 0)	x		
10 min	x		
15 min		x	
20 min			x
30 min	x		
45 min			x
1 h		x	
1.25 h	x		
1.5 h			x
2 h		x	
2.5 h			x
3 h		x	
4 h			x

6 h			x
10 h		x	
16 h	x		
24 h	x		
36 h		x	

The samples were collected on heparin tubes and then centrifuged within the hour for 7-8 min at 1600 g at 4°C. At each sampling time, the plasma of the 6 rats of the group is "pooled".

☐ Methods for assaying the UPA in the plasma samples

- 5 The ulipristal acetate was assayed by LC/MS/MS under the following conditions:
- Mobile phase: Methanol/distilled water (70/30, V/V) + 1% acetic acid
 - Column: BDS Hypersil phenyl, 100 x 2.1 mm, 5 µm
 - Elution mode: isocratic
 - Flow rate: 0.400 ml/min
- 10 - Injection volume: 10.0 µl
- Needle cleaning liquid: Acetonitrile/isopropanol/acetone (40/40/20, V/V/V)

2. Results

- Table 9 below presents the pharmacokinetics results obtained. The co-micronisation makes it possible to increase the bioavailability of the UPA: The AUC_{0-t} and the AUC_{0-inf} for the co-micronisate are approximately 15% to 20% higher than the AUCs obtained for the micronised UPA. The UPA absorption rate is also faster with the co-micronisate (T_{max} = 1 h) than with the micronised UPA (T_{max} = 1.25 h). Notably, the co-micronisation does not significantly increase the C_{max} (variation of +3.6% only). These *in vivo* results are coherent with the *in vitro* dissolution results previously obtained.

Table 9: Pharmacokinetics results

	<u>Co-micronisate</u> <u>UPA/SDS 1/1</u>	<u>Micronised UPA</u>	<u>Variations</u>
C_{max} (ng/ml)	463	447	+ 3.6%
T_{max} (h)	1.0	1.25	- 20%
AUC_{0-t} (h.ng/ml)	1595	1340	+ 19%
AUC_{inf} (h.ng/ml)	1610	1383	+16.4%

In conclusion, the co-micronisation in the presence of SDS makes it possible to significantly improve the bioavailability of the UPA, without however drastically increasing the C_{max}.

The co-micronisation of UPA in the presence of SDS makes it possible to obtain a novel matrix of active principle with improved bioavailability, which should make it possible to reduce the
5 doses of UPA to be administered to the patient in order to achieve the desired therapeutic effects. This novel matrix should also make it possible to develop new UPA administration schemes.

Example 6: Pharmaceutical compositions integrating the co-micronisate according to the invention

1. Materials and methods

In order to confirm the gain in UPA dissolution, even after formulation of the co-micronisate, tablets containing 5 mg of ulipristal acetate (non-film-coated) were produced by direct compression and tested under the same *in vitro* dissolution conditions as those described in Example 1, with the exception of the volume of the dissolution medium, which in this case is 500 ml. The composition of the tablets is given in Table 10 below.

Table 10: composition of the tablets prepared

	<u>Tablet No. 1 (invention)</u>		<u>Tablet No. 2 (invention)</u>	
Ingredients	mg/tablet	% by weight	mg/tablet	% by weight
UPA/SDS 1/1	10.00	6.7	10.00	6.7
Microcrystalline cellulose	92.45	61.6	87.50	58.3
Mannitol	43.50	29.0	43.50	29.0
Sodium croscarmellose	2.55	1.7	7.50	5.0
Magnesium stearate	1.50	1.0	1.50	1.0
Total	150.00	100.0	150.00	100.0

2. Results

The *in vitro* dissolution profiles are illustrated in Figure 4 and presented in Table 11 below.

Table 11: Results of the *in vitro* dissolutions for tablets No. 1 and No. 2

	Percentages of UPA dissolution	
Time (min)	Tablet No. 1 (invention)	Tablet No. 2 (invention)
0	0	0
3	17.3	20.6
5	31.4	43.1
7.5	48.2	65.5
10	60.7	81.7
15	70.2	85.9
20	74.2	87.3
30	78.2	88.6
45	82.2	89.9
60	84.7	90.9

The tablets according to the invention exhibit high rates and a high final degree of UPA release. These results confirm that the co-micronisation of UPA with SDS makes it possible to improve its solubilisation properties, even after integration into a complex pharmaceutical composition. Finally, during the preparation of the tablets, the applicant observed that the co-micronisate product was much easier to formulate than the UPA micronised without SDS. Indeed, the applicant noted that the formulation used to prepare tablets No. 1 and No. 2 was fluid and easily compressible even in the absence of talc (flow agent) and of binder. In other words, the co-micronisate according to the invention can be easily formulated, even in the absence of flow agent.

3. Comparative tests

3 additional batches of tablets were prepared by direct compression. The batch of tablets No. 3 corresponds to the invention. The batches No. 4 and No. 5 correspond to comparative batches since they are free of co-micronisate. Tablets No. 4 comprise micronised UPA and SDS, while tablets No. 5 comprise micronised UPA only.

Table 12: Examples of tablets

	Tablet No. 3 (invention)	Tablet No. 4 (comparative)	Tablet No. 5 (comparative)
Ingredients	mg/tablet	mg/tablet	mg/tablet
Micronised UPA	0	5	5
SDS	0	5	0
Co-micronisate <u>UPA/SDS 1/1</u>	10	0	0
Microcrystalline cellulose	88.25	88.25	93.25
Mannitol	43.5	43.5	43.5
Crospovidone	7.5	7.5	7.5
Magnesium stearate	0.75	0.75	0.75
TOTAL	150	150	150

The *in vitro* dissolution profiles for these tablets were obtained according to the conditions described in point 1. above and are illustrated in Table 13 below.

- 5 Table 13: Results of the *in vitro* dissolutions for tablets No. 3 (invention), No. 4 (comparative) and No. 5 (comparative)

	Percentages of UPA dissolution		
Time (min)	Tablet No. 3 (invention)	Tablet No. 4 (comparative)	Tablet No. 5 (comparative)
0	0	0	0
3	6.8	12.6	26.7
5	54.3	56.2	43
7.5	79.2	60.5	46
10	87.2	62.6	47.8
15	88.9	65.4	49.6
20	89.8	67.5	50.9
30	90.9	70.7	52.7
45	92.1	74.7	55.3
60	93.1	78.3	57.3

It appears that the rate and the final degree of dissolution of the UPA for the tablet according to the invention (tablet No. 3) are higher than those of tablet No. 4 (mixture of SDS and of micronised UPA) and of tablet No. 5 (micronised UPA).

These results confirm the specific effect of the co-micronisation in the presence of a surfactant, such as SDS, on the UPA solubilisation properties, even after incorporation into a pharmaceutical composition.

For information, it is specified that the compositions according to the invention that are illustrated in Tables 10 and 12 can be used, for example, in regular contraception or on-demand contraception, or else as a medicament, for example for the treatment of gynaecological disorders such as uterine fibroma.

Example 7: Additional examples of compositions according to the invention

Table 14 hereinafter presents an additional example of a composition according to the invention. This composition can be prepared and shaped by direct compression.

Table 14: additional example of a composition according to the invention

Composition	mg/tablet	% by weight
Co-micronisate UPA/SDS 1/1	60 (of which 30 mg of UPA)	40
Microcrystalline cellulose	38.25	25.5
Mannitol	43.5	29
Crospovidone	7.5	5
Magnesium stearate	0.75	0.5
Total	150	100

This composition can be used as an emergency contraceptive.

Other examples of tablets are provided hereinafter. These tablets can be prepared by direct compression.

Composition	mg/tablet	% by weight
Co-micronisate UPA/SDS 1/1	60.0 (of which 30 mg of UPA)	50
Lactose	49.2	41
Crospovidone	9.6	8
Magnesium stearate	1.2	1
Total	120.0	100

Composition	mg/tablet	% by weight
Co-micronisate UPA/SDS 1/1	8.00 (of which 4 mg of UPA)	12.5

Lactose	28.80	45
Mannitol	20.48	32
Sodium croscarmellose	6.40	10
Magnesium stearate	0.32	0.5
Total	64.00	100

Composition	mg/tablet	% by weight
Co-micronisate UPA/SDS 1/1	20.0 (of which 10 mg of UPA)	25
Lactose	32.0	40
Microcrystalline cellulose	22.4	28
Crospovidone	4.8	6
Magnesium stearate	0.8	1
Total	80.0	100

Composition	mg/tablet	% by weight
Co-micronisate UPA/SDS 6/4	10.00 (of which 6 mg of UPA)	6.7
Microcrystalline cellulose	92.45	61.6
Mannitol	43.50	29
Sodium croscarmellose	2.55	1.7
Magnesium stearate	1.50	1
Total	150	100

Composition	mg/tablet	% by weight
Co-micronisate UPA/SDS 7/3	42.85 (of which 30 mg of UPA)	30.6
Microcrystalline cellulose	45.40	32.4
Mannitol	43.5	31.1
Crospovidone	7.5	5.4
Magnesium stearate	0.75	0.5
Total	140	100

Patentkrav

1. Ko-mikroniseringsprodukt som omfatter:
 - 5 - en aktiv bestanddel valgt fra gruppen bestående av ulipristalacetat, en metabolitt av ulipristalacetat, og blandinger derav, og
 - en farmasøytisk akseptert fast surfaktant valgt fra C₈-C₂₀ alkyl- sulfatsalter og blandinger derav.
- 10 2. Ko-mikroniseringsprodukt ifølge krav 1, karakterisert ved at vektforholdet mellom den aktive bestanddel og surfaktanten er inkludert i et område fra 0,1 til 10, foretrukket fra 0,5 til 4.
- 15 3. Ko-mikroniseringsprodukt ifølge hvilket som helst av kravene 1 til 2, karakterisert ved at surfaktanten er natriumdodecylsulfat.
4. Ko-mikroniseringsprodukt ifølge hvilket som helst av kravene 1 til 3, karakterisert ved at den aktive bestanddel er valgt fra gruppen bestående av ulipristalacetat, 17 α -acetoksy-11 β -(4-N-metylaminofenyl)-19-norpregna-4,9-dien-20 3,20-dion, 17 α -acetoksy-11 β -(4-aminofenyl)-19-norpregna-4,9-dien-3,20-dion og blandinger derav.
5. Ko-mikroniseringsprodukt ifølge hvilket som helst av kravene 1 til 4, karakterisert ved at:
 - 25 - surfaktanten er natriumdodecylsulfat, og
 - den aktive bestanddel er ulipristalacetat.
6. Ko-mikroniseringsprodukt ifølge hvilket som helst av kravene 1 til 5, som har
 - en d₅₀ på mindre enn 20 μ m, foretrukket mindre enn 15 μ m, og/eller
 - 30 - en d₉₀ på mindre enn 50 μ m, foretrukket mindre enn 40 μ m.
7. Fremgangsmåte for fremstilling av et ko-mikroniseringsprodukt som angitt i hvilket som helst av kravene 1 til 6, omfattende trinnene som består i:

- a) tilveiebringelse av en aktiv bestanddel valgt fra gruppen bestående av ulipristalacetat, en metabolitt av ulipristalacetat og blandinger derav,
- b) blanding av den aktive bestanddel i trinn a) med en surfaktant valgt fra C₈-C₂₀ alkylsulfatsalter og blandinger derav, og
- 5 c) ko-mikronisering av blandingen oppnådd i trinn b).

8. Fremgangsmåte for fremstilling av et ko-mikroniseringsprodukt ifølge krav 7, karakterisert ved at i trinn a) blir den aktive bestanddel tilveiebragt i en ikke-mikronisert form eller i en mikronisert form.

10

9. Farmasøytisk preparat som omfatter et ko-mikroniseringsprodukt som angitt i ett av kravene 1 til 6 og en farmasøytisk akseptabel eksipiens.

15

10. Farmasøytisk preparat ifølge krav 9, karakterisert ved at den farmasøytisk akseptable eksipiens er valgt fra gruppen som består av et fortynningsmiddel, et bindemiddel, et strømningsmiddel, et smøremiddel, et disintegreringsmiddel og blandinger derav.

20

11. Farmasøytisk preparat ifølge krav 9 eller 10, som omfatter fra:

- 0,5% til 80% ko-mikroniseringprodukt,
- 0% til 10% disintegreringsmiddel,
- 15% til 95% fortynningsmiddel, og
- 0% til 5% smøremiddel,

hvor prosentene er uttrykt på vektbasis i forhold til den totale vekten av blandingen.

25

12. Farmasøytisk preparat ifølge hvilket som helst av kravene 9 til 11, karakterisert ved at det omfatter fra 1 mg til 100 mg, foretrukket fra 1 mg til 40 mg, aktiv bestanddel pr doseringsenhet.

30

13. Farmasøytisk preparat ifølge hvilket som helst av kravene 9 til 12, karakterisert ved at det er egnet for oral administrering.

14. Farmasøytisk preparat ifølge hvilket som helst av kravene 9 til 13, karakterisert ved at det er i form av et pulver, et granulat, en belagt eller ubelagt tablett eller en

kapsel.

15. Ko-mikroniseringsprodukt ifølge hvilket som helst av kravene 1 til 6, eller
farmasøytisk preparat ifølge hvilket som helst av kravene 9 til 14, for anvendelse som
5 et prevensjonsmiddel.

16. Ko-mikroniseringsprodukt ifølge hvilket som helst av kravene 1 til 6, eller
farmasøytisk preparat ifølge hvilket som helst av kravene 9 til 14, for anvendelse ved
behandling eller forebygging av en gynekologisk lidelse som foretrukket påvirker
10 livmoren.




FIGURE 1




FIGURE 2





FIGURE 3

**FIGURE 4**